Trending Aesthetic Treatments: What Patients Are Asking For

The surge in GLP-1 agonist use (semaglutide, tirzepatide) has created a secondary market for aesthetic refinement. Patients losing 20–50+ pounds are seeking treatments to address loose skin, cellulite, and localized fat deposits—areas that diet and exercise alone won't fix. Galderma reported a 25% year-over-year lift in aesthetics sales in H1 2026, explicitly attributing growth to GLP-1 adoption. This translates to increased demand for radiofrequency microneedling (RF microneedling), cryolipolysis, acoustic pulse therapy, and injectable biostimulators (PLLA, CaHA) that trigger collagen remodeling. The economics are favorable: these procedures command premium pricing ($800–$3,000 per session), require minimal inventory, and drive repeat visits. However, patient expectations are high—they expect visible improvement in skin quality and contour within 2–4 weeks. Ensure your clinical team can deliver consistent results and manage post-treatment downtime (RF microneedling typically requires 3–5 days of erythema and edema). Track your GLP-1 patient cohort separately to measure treatment uptake and refine your messaging.

The neuromodulator category is fragmenting. Boey (prabotulinumtoxinA-psmf, AbbVie) secured EU approval in 2026 and is pending FDA review, offering onset in 24–48 hours versus the standard 3–7 days for botulinum toxin A. Xeomin (incobotulinumtoxinA, Revance) continues to gain share among patients reporting toxin resistance or seeking a preservative-free option. Jeuveau (prabotulinumtoxinA, Evolus) remains a lower-cost alternative. From a practice perspective, this fragmentation creates both opportunity and complexity. Rapid-onset products appeal to patients with last-minute events and those seeking "event botox," but they typically command a 15–25% price premium and may require separate inventory management and patient education. Toxin resistance—real or perceived—is driving some patients to rotate products or seek higher units. Before adding a second or third neuromodulator, calculate the inventory carrying cost, shelf-life risk, and patient volume needed to justify the SKU. Most practices find that 80% of toxin demand is met by one primary product; the second product captures an incremental 10–15% of volume at higher margin but also introduces complexity. Ensure your EMR and consent forms clearly document which product was used to track outcomes and patient preference.

The neck and upper chest have emerged as a distinct treatment category, no longer bundled with "face." Skinvive by Juvéderm (hyaluronic acid microdroplet injectable, AbbVie) received FDA approval in 2026 specifically for neck-line improvement, signaling regulatory and commercial recognition of this market. Patients are increasingly aware of the neck's age-revealing properties and are willing to invest in preventive and corrective treatments. This category includes HA fillers (traditional and microdroplet formulations), RF microneedling, chemical peels, and biostimulators. From a revenue standpoint, neck treatments are high-margin: a single Skinvive session ($800–$1,200) requires minimal product (0.5–1 syringe) and takes 15–20 minutes. Positioning neck treatments as a standalone service—not an add-on—increases perceived value and encourages upsell. Update your treatment menus and pricing to reflect neck as a distinct area. Train your injectors on the anatomy (platysma, lymphatic drainage, skin thickness) to avoid complications. Consider bundling neck treatments with facial injectables in package pricing to increase average transaction value.

Patient demand for non-invasive skin tightening is at a multi-year high. Cynosure Lutronic's next-generation monopolar RF platform and Alma Lasers' Harmony platform (launched 2026) are driving competitive intensity and clinical innovation in the RF space. Patients want visible skin tightening without surgery, and RF microneedling delivers: fractional RF energy penetrates to the dermis and subcutis, triggering collagen synthesis and remodeling over 8–12 weeks. The treatment requires 3–5 sessions spaced 4–6 weeks apart, creating predictable recurring revenue. Device acquisition cost is substantial ($80,000–$200,000 depending on platform and financing), but break-even is achievable at 15–25 treatments per month. Before investing, validate demand in your market: survey existing patients, review competitor pricing ($1,500–$3,000 per session), and model patient volume based on your current aesthetic patient base and referral network. RF microneedling is not a commodity—clinical outcomes depend heavily on operator skill, device settings, and post-treatment care. Ensure your team receives manufacturer training and maintains competency. Consider starting with a leased or used device to test demand before committing capital.

Poly-L-lactic acid (PLLA) and calcium hydroxylapatite (CaHA) biostimulators are gaining traction as patients seek longer-lasting results than HA fillers and appreciate the gradual, natural-looking improvement. These products work by triggering the body's own collagen production, with results visible over 4–8 weeks and lasting 12–24+ months. Galderma's Radiesse (CaHA) and Sculptra (PLLA) dominate this category, though new entrants are emerging. From a practice economics standpoint, biostimulators command higher per-syringe pricing ($600–$900) than traditional HA fillers ($300–$600), but require patient education about the delayed onset and gradual results—not ideal for patients seeking immediate gratification. Biostimulators also require precise injection technique and anatomic knowledge to avoid nodules or overcorrection. Position biostimulators as a premium option for patients seeking longevity and natural aging, not as a replacement for HA fillers. Many practices use a hybrid approach: HA for immediate volume, biostimulators for long-term collagen support. Ensure your team has hands-on training and that your consent forms clearly set expectations about timeline and results. Track patient satisfaction and complication rates separately for biostimulators to refine your protocols.

Several regulatory and competitive developments will shape trending treatments over the next 12–24 months. Relabotulinum toxinA (Galderma's next-generation botulinum toxin) is under FDA BLA review and may offer improved potency or duration. Hugel Aesthetics is expanding its US presence with direct sales for Letybo (botulinum toxin A) and K-TOX, signaling new competitive pressure in the toxin market. InMode is under acquisition review (Steel Partners offered $16.75/share in 2026), which may affect device availability and pricing. L'Oreal is increasing its stake in Galderma to 20%, suggesting long-term consolidation in the injectables space. For practice owners, this means: monitor FDA approvals and new product launches quarterly; evaluate new competitors on clinical differentiation and pricing, not just brand; diversify your supplier relationships to avoid single-vendor dependency; and stay current with your state's scope-of-practice regulations, which may evolve as new products enter the market. Join industry associations (ASDS, ASLMS) to access regulatory updates and peer benchmarking data. Attend key conferences (annual meetings) to evaluate new devices and injectables firsthand before committing capital.

Not every trending treatment is right for your practice. Use this framework to evaluate adoption: (1) Clinical fit: Does the treatment align with your scope of practice and your team's skill level? RF microneedling requires operator expertise; rapid-onset toxins require patient education. (2) Patient demand: Survey your existing patient base and review your top 20 patient charts—are they asking for this treatment? (3) Economics: Model the investment (device, inventory, training, marketing) against projected patient volume and margin. Break-even timeline should be 12–24 months. (4) Competitive positioning: What are your top three competitors offering? Are you at risk of losing patients if you don't add this treatment? (5) Operational capacity: Do you have staff bandwidth to master a new treatment, or will you need to hire? (6) Reimbursement: Is this treatment cash-pay only, or does your payer mix cover it? Trending treatments are typically cash-pay, which simplifies reimbursement but requires strong patient communication about out-of-pocket cost. Document your decision and revisit it quarterly. If a trend doesn't gain traction after 6 months and 10–15 patient inquiries, it may not be right for your market.